Want to see IL:NVLG full AI Analyst Report?
NVLG Stock Chart & Stats
76.50
0.20(0.26%)
At close: 4:00 PM EDT
76.50
0.20(0.26%)
Day’s Range― - ―
52-Week Range66.30 - 136.90
Previous CloseN/A
Volume545.85K
Average Volume (3M)559.85K
Market Cap
₪436.80M
Enterprise Value355.02M
Total Cash (Recent Filing)₪204.46M
Total Debt (Recent Filing)₪171.19M
Price to Earnings (P/E)―
Beta0.75
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.58%
Share Statistics
EPS (TTM)N/A
Shares Outstanding510,874,760
10 Day Avg. Volume742,978
30 Day Avg. Volume559,853
Financial Highlights & Ratios
PEG Ratio-1.73
Price to Book (P/B)1.80
Price to Sales (P/S)0.36
P/FCF Ratio-18.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong TTM Revenue GrowthRevenue growth of 56.4% indicates strong recent expansion in the distribution business and can improve operating scale if sustained. A larger revenue base may support broader customer reach, better absorption of fixed costs, and continued investment in the company’s operating platform over coming quarters.
Rebound In Cash GenerationThe return to positive operating and free cash flow provides internal funding for working capital, investment, and other business needs without relying entirely on external financing. This improves near-term financial flexibility, although the durability of the rebound depends on more consistent cash conversion.
Manageable Balance-Sheet LeverageDebt-to-equity of about 0.49 suggests leverage is moderate and the balance sheet retains a meaningful equity cushion. This supports financial resilience and leaves more capacity to manage operating volatility, fund growth, or absorb weaker earnings than a highly leveraged capital structure would allow.
Bears Say
Profitability DeteriorationThe move to slightly negative net income, together with lower gross and operating profitability, shows that revenue expansion is not currently translating into durable earnings power. Thin distributor margins leave limited room for execution setbacks and may constrain reinvestment, dividends, or balance-sheet strengthening.
Volatile Cash ConversionAlthough current cash generation is positive, the sharp year-to-year swing and materially lower free-cash-flow growth reduce confidence that cash conversion is structurally dependable. Continued volatility could make working-capital funding and investment planning more difficult, especially while earnings remain weak.
Negative Returns On EquityA slightly negative TTM ROE indicates that shareholder capital is not presently producing positive accounting returns, despite the company retaining a sizable equity base. The deterioration from prior years signals weaker capital efficiency and may limit the company’s ability to compound value unless profitability recovers.
Novolog News
NVLG FAQ
What was Novolog (Pharm UP 1966) Ltd.’s price range in the past 12 months?
Novolog (Pharm UP 1966) Ltd. lowest stock price was 66.30 and its highest was 136.90 in the past 12 months.
What is Novolog (Pharm UP 1966) Ltd.’s market cap?
Novolog (Pharm UP 1966) Ltd.’s market cap is ₪436.80M.
When is Novolog (Pharm UP 1966) Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Novolog (Pharm UP 1966) Ltd.’s earnings last quarter?
Currently, no data Available
Is Novolog (Pharm UP 1966) Ltd. overvalued?
According to Wall Street analysts Novolog (Pharm UP 1966) Ltd.’s price is currently Overvalued.
Does Novolog (Pharm UP 1966) Ltd. pay dividends?
Novolog (Pharm UP 1966) Ltd. pays a Semiannually dividend of 1.957 which represents an annual dividend yield of 4.58%. See more information on Novolog (Pharm UP 1966) Ltd. dividends here
What is Novolog (Pharm UP 1966) Ltd.’s EPS estimate?
Novolog (Pharm UP 1966) Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Novolog (Pharm UP 1966) Ltd. have?
Novolog (Pharm UP 1966) Ltd. has 510,874,760 shares outstanding.
What happened to Novolog (Pharm UP 1966) Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Novolog (Pharm UP 1966) Ltd.?
Currently, no hedge funds are holding shares in IL:NVLG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Novolog (Pharm UP 1966) Ltd.
Novolog (Pharm-Up 1966) Ltd provides healthcare services in Israel. The company operates through three divisions: Logistics, Healthcare Services, and Digital. The Logistics division engages in the import and distribution of pharmaceuticals and medical products; logistics of clinical trials and related services; provision of pharmaceutical services to customers; and sterilization and validation processes of consumable medical equipment. The Healthcare Services division provides personalized medicine, medical and diagnostic laboratory, and other medical services to patients, health organizations, insurance companies, multinational companies, and government bodies. The Digital division identifies and develops technological tools for health services; deals with making medical information accessible to the public through medical websites; promotes digital presence for clinics, doctors therapists, and medical bodies; provides services and management tools; and operates and markets digital platforms for doctors and clinics. In addition, the company provides appointment scheduling, calendar management, and telemedicine meeting management. Novolog (Pharm-Up 1966) Ltd was incorporated in 1966 and is headquartered in Modi'in-Maccabim-Re'ut, Israel.